Abstract
Temozolomide (TMZ) and carmustine (BCNU), cancer-drugs usually used in the treatment of gliomas, are DNA-methylating agents producing O6-methylguanine. It has been shown that 06-methylguanine triggers DNA mismatch repair and in turn induce apoptosis and senescence, respectively, over a 4 and 6 days period [Y. Hirose, M.S. Berger, R.O. Pieper, p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells, Cancer Res. 61 (2001) 1957-1963; W. Roos, M. Baumgartner, B. Kaina, Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1, Oncogene 23 (2004) 359-367]. Here we show that TMZ and BCNU have an earlier effect on nuclear organization and chromatin structure. In particular, we report that TMZ and BCNU induce clustering of pericentromeric heterochromatin regions and increase the amount of heterochromatic proteins MeCP2 and HP1alpha bound to chromatin. These drugs also decrease global levels of histone H3 acetylation and increase levels of histone H3 trimethylated on lysine 9 (H3-triMeK9). These events precede the senescence status. We conclude that TMZ and BCNU efficacy in glioma treatment may implicate a ...Continue Reading
References
Jan 15, 1995·Genes & Development·R C AllshireG Cranston
Feb 21, 1997·Cell·X NanA Bird
Aug 4, 1998·Molecular Pharmacology·S D'AtriJ Jiricny
Nov 27, 1999·British Journal of Cancer·M BradaD Cutler
Feb 15, 2001·Nature Cell Biology·A TaddeiG Almouzni
Mar 10, 2001·Nature·M LachnerT Jenuwein
Nov 10, 2001·Cell·A H PetersT Jenuwein
Jun 18, 2003·Cell·Masashi NaritaScott W Lowe
Nov 25, 2003·Genes & Development·Frauke GreilBas van Steensel
Jan 16, 2004·Oncogene·Wynand RoosBernd Kaina
Apr 9, 2004·Nature Reviews. Molecular Cell Biology·Christèle Maison, Geneviève Almouzni
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 9, 2005·The Journal of Cell Biology·Alessandro BreroM Cristina Cardoso
Sep 27, 2005·Experimental Cell Research·Rémi TerranovaAmanda G Fisher
Jan 10, 2006·Developmental Cell·Eran MeshorerTom Misteli
Jun 26, 2007·Nature·Daniel A KosterNynke H Dekker
Nov 7, 2007·The Journal of Cell Biology·Junjie Lu, David M Gilbert
Aug 2, 2008·The New England Journal of Medicine·Patrick Y Wen, Santosh Kesari
Oct 24, 2008·The New England Journal of Medicine·Bruce R Bistrian
Citations
Feb 23, 2011·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Ching-Hsein ChenJen-Tsung Yang
Aug 18, 2010·Acta Neuropathologica·Markus J RiemenschneiderGuido Reifenberger
Mar 23, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Mehmet TaspinarHasan Caglar Ugur
Sep 12, 2012·Oncogene·Y WangX Bi
Jun 8, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gaspar J KitangeJann N Sarkaria
Apr 23, 2013·Toxins·Kashif Jilani, Florian Lang
Sep 24, 2011·Brain Pathology·Bastian MalzkornGuido Reifenberger
Oct 26, 2012·The European Journal of Neuroscience·Francesca InverardiCarolina Frassoni
May 9, 2012·Journal of Neurochemistry·Caroline HappoldMichael Weller
Mar 23, 2011·International Journal of Cancer. Journal International Du Cancer·Jörg FelsbergUNKNOWN German Glioma Network
Apr 8, 2014·Genes, Chromosomes & Cancer·Vera RiehmerUNKNOWN German Glioma Network
Jun 24, 2014·Platelets·Jie ZhangKesheng Dai
Aug 22, 2012·The Journal of International Medical Research·X-Y LuP-S Lu
Jan 1, 2011·Cancers·Irfan A Qureshi, Mark F Mehler
Jul 28, 2019·Brain : a Journal of Neurology·Guo-Zhong YiSongtao Qi
Apr 3, 2020·Cancers·Tareq SalehDavid A Gewirtz
Jul 29, 2018·Nature Communications·Xiaoyue ChenZhiguo Zhang
May 15, 2010·Journal of Neuro-oncology·Ayhan BilirAkin Sabanci
May 10, 2018·Scientific Reports·D M TiekR B Riggins
Aug 8, 2019·Cancer Research·Lydia Robinson-GarciaJoanna I Loizou